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Abstract
Background: Standard treatment of advanced ovarian cancer is surgery and chemotherapy. The goal of surgery is
to remove all macroscopic tumour, as the amount of residual tumour is the most important prognostic factor for
survival. When removal off all tumour is considered not feasible, neoadjuvant chemotherapy (NACT) in
combination with interval debulking surgery (IDS) is performed. Current methods of staging are not always
accurate in predicting surgical outcome, since approximately 40% of patients will have more than 1 cm residual
tumour after primary debulking surgery (PDS). In this study we aim to assess whether adding laparoscopy to the
diagnostic work-up of patients suspected of advanced ovarian carcinoma may prevent unsuccessful primary
debulking surgery for ovarian cancer.
Methods: Multicentre randomized controlled trial, including all gynaecologic oncologic centres in the Netherlands
and their affiliated hospitals. Patients are eligible when they are planned for PDS after conventional staging.
Participants are randomized between direct PDS or additional diagnostic laparoscopy. Depending on the result of
laparoscopy patients are treated by PDS within three weeks, followed by six courses of platinum based
chemotherapy or with NACT and IDS 3-4 weeks after three courses of chemotherapy, followed by another three
courses of chemotherapy. Primary outcome measure is the proportion of PDS’s leaving more than one centimetre
tumour residual in each arm. In total 200 patients will be randomized. Data will be analysed according to intention
to treat.
Discussion: Patients who have disease considered to be resectable to less than one centimetre should undergo
PDS to improve prognosis. However, there is a need for better diagnostic procedures because the current number
of debulking surgeries leaving more than one centimetre residual tumour is still high. Laparoscopy before starting
treatment for ovarian cancer can be an additional diagnostic tool to predict the outcome of PDS. Despite the
absence of strong evidence and despite the possible complications, laparoscopy is already implemented in many
countries. We propose a randomized multicentre trial to provide evidence on the effectiveness of laparoscopy
before primary surgery for advanced stage ovarian cancer patients.
Trial registration: Netherlands Trial Register number NTR2644
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Background
Epithelial ovarian cancer (EOC) is the leading cause of
death in gynaecologic malignancies. Ovarian cancer is
usually diagnosed in an advanced stage, when tumour
has spread from the ovaries throughout the abdominal
cavity or into the liver parenchyma and pleural cavity
(FIGO stage III or IV respectively). In advanced stage
disease many patients have multiple tumour deposits
spread out over the peritoneum, peritoneal carcinosis.
Although survival of early stages is high, the survival of
advanced stages is low. Despite an initial response rate
of 80% after first line treatment, recurrences occur in
70% of patients, and the expected overall survival is 2 to
4 years.
Standard treatment of patients with advanced disease
is primary cytoreductive (debulking) surgery (PDS),
intended to remove all visible tumor localizations [1].
Surgery is followed by six courses of chemotherapy con-
sisting of Paclitaxel and Carboplatin. Result of debulking
surgery is the most important prognostic factor for sur-
vival [1-4] Leaving no residual tumour gives the best
survival. However, if complete resection is not possible,
the goal of surgery is to achieve at least residual disease
smaller than one centimetre in diameter. The present
rate of patients with residual tumour smaller than one
centimetre in Europe is only 20-62% [5,6]. In case a
tumour deposit of more than one centimetre is left at
PDS some patients will be operated again after three
courses of chemotherapy, a so called interval debulking
surgery (IDS). Only those patients for who PDS was not
considered to a maximal attempt by a gynaecological
oncologist are candidate for this intervention [7]. A PDS
leaving more than one centimetre of tumour is an
unsuccessful laparotomy leading to more morbidity
without gain in survival. It lengthens hospital stay and
time of treatment and increases costs and should there-
fore be avoided.
Computed tomography (CT) is now used in pre-
operative staging of patients with an ovarian tumour
for predicting operability and to determine treatment
[8-10]. CT criteria have been developed which are
used to select patients for primary surgery [9]. Bristow
et al. developed a model based on 13 criteria, like peri-
toneal thickening or bowel mesentery involvement,
achieving an overall accuracy of 93% in predicting suc-
cessful cytoreduction [11]. However, this result could
not be achieved using the same criteria in another
patient population [12]. Recently, Ferrandina developed
a predictive score based on CT criteria as well as per-
formance status [9]. Depending on the model and the
predictive score used, 33% to 48% of patients would
have had a suboptimal debulking, despite the predic-
tion that complete removal would be feasible.
Although CT is at present the most predictive
procedure, it is not accurate enough to guide clinical
management. [12,13]
Recently a randomized study of the European Organi-
zation of Research and Treatment of Cancer-Gynaecolo-
gical Cancer Group (EORTC-GCG) and the NCIC-
Clinical Trials Group comparing PDS and chemotherapy
with neoadjuvant chemotherapy (NACT) followed by
IDS was conducted [6]. Although survival was compar-
able in both groups, a subgroup analysis showed that
patients with metastases with a diameter of less than
five cm at start of primary debulking have a better prog-
nosis when treated by PDS. Emphasizing the fact that
PDS should be the standard treatment and that neoadju-
vant chemotherapy should be reserved to patients in
whom optimal debulking is deemed not feasible or who
can not tolerate the procedure [6,14]. Therefore, selec-
tion of patients is very important and could be done by
using laparoscopy to predict operability results [6,15].
Several prospective and retrospective studies have
investigated the use of laparoscopy to predict outcome
of debulking surgery. In a pilot study by Fagotti et al.
[16] laparoscopy predicted debulking leaving tumour
residual more than one centimetre in 100% of cases and
debulking surgery with no macroscopic tumour left in
89% of cases [16]. With these data Fagotti et al. devel-
oped a prediction model with accuracy for prediction of
unsuccessful debulking between 69% and 75% depend-
ing on the cutoff level of the Predictive Index Value
used [17]. However, validation of this prediction model
in another study population by Brun et al. showed that
56% of patients who were thought to have debulking
until less than 1 cm of tumour residual underwent a
unsuccessful resection [18].
Despite the absence of strong evidence and despite
possible complications laparoscopy is already implemen-
ted in many countries. In this respect, we propose a ran-
domized controlled clinical trial in which the outcome
of PDS after diagnostic laparoscopy is compared with
the outcome of PDS after standard diagnostic work-up.
Objective
The aim of this study is to asses whether diagnostic
laparoscopy can prevent unsuccessful debulking surgery
in patients with advanced ovarian cancer. This study
will also evaluate whether adding laparoscopy is cost-
effective, improves quality of life and generates less mor-
bidity in this population as compared to standard diag-
nostic work-up.
Methods/Design
Trial Design
This study is a multicentre prospective randomized con-
trolled trial in which all nine Dutch gynaecological-
oncology centres and affiliated hospitals are participating.
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Patients with advanced ovarian cancer planned for PDS
will be randomized to PDS or an additional diagnostic
laparoscopy followed by either PDS or NACT and IDS.
The rate of futile PDS in both groups (Figure 1) will be
compared. A debulking surgery is regarded futile when
the diameter of the largest residual tumour deposition
is larger than 1 cm in diameter. The study is conducted
according to the principles of the Declaration of Hel-
sinki and in accordance with the Medical Research
Involving Human Subjects Act (WMO) and has been
approved by the ethics committee of the Academic
Medical Centre Amsterdam (ref. no MEC 10/183). The
protocol is registered in the Netherlands trial register
number NTR 2644
Eligibility criteria
Inclusion criteria patients
Patients with advanced ovarian cancer who are planned
for primary debulking surgery are eligible for this study.
Patients have to be able to give written informed con-
sent and aged between 18 and 80 years.
Exclusion criteria patients
Contraindications for PDS are exclusion criteria for this
study. These include a WHO performance status of ≥ 3
and a large immobile pelvic tumour giving the impres-
sion that complete debulking is not feasible. Further
exclusion criteria are imaging techniques suggestive of
intrahepatic metastatic disease of > one centimetre,
extra-abdominal metastatic disease (excl inguinal lymph
nodes or pleural fluid), peri-aortic lymphadenopathy lar-
ger than one centimetre above the level of the renal
veins, extensive peritoneal carcinomatosis at the level of
the diaphragm giving the impression that surgery leav-
ing no macroscopic tumour residual is impossible and
extensive bowel mesentery involvement.
Patient recruitment, randomization and collection of data
Eligible patients are identified and counseled by the
gynaecological staff of participating hospitals. Patients
suspected of having advanced ovarian cancer are usually
referred to a general gynaecologist. According to the
national guideline for ovarian cancer, appropriate treat-
ment as well as timing and localization of surgery will
be discussed with a gynaecological oncologist from a
centre hospital. All patients will undergo conventional
staging, consisting of medical history, complete physical
and gynaecological examination, ultrasound examina-
tion, assessment of CA 125 and CEA serum levels, chest
X-ray and contrast enhanced abdominopelvic CT. CT
scanning will be performed using the standard equip-
ment in the hospital in which the patients will undergo
laparoscopy. All CT’s will be evaluated by an experi-
enced radiologist and will be reviewed by the centre
radiologist.
The decision that a patient is eligible for PDS will be
made by the gynaecological oncologist in collaboration
with the referring gynaecologist on the basis of all avail-
able information. All patients considered to be optimally
operable will be offered PDS and will be asked to parti-
cipate in this study. After written informed consent has
been obtained, randomization will take place.
Randomization is performed by accessing a central
internet-based randomization program and is stratified
by gynaecologic-oncologic centre hospital. Patients will
be randomly allocated in a 1:1 ratio to two groups. The
first group will undergo PDS followed by chemotherapy
and the second group will undergo an additional diag-
nostic laparoscopy. At study entry baseline demographic
characteristics, medical history and findings of
Women suspected 
of ovarian cancer
Primary debulking 
surgery feasible
No laparoscopy
Debulking surgery 
not feasible
Debulking surgery 
feasible
Primary outcome:
futile laparotomy #
Secondary outcome:
frequency of complete cytoreductive surgery, 
survival, quality of life, days in hospital, morbidity 
and costs
Laparoscopy
Conventional
staging
Primary debulking Primary debulking Neoadjuvantechemotherapy
Randomization
Figure 1 LapOvCa-trial design. * = Physical examination,
ultrasound, tumor markers, chest X-ray, abdominal CT. # = Largest
residual tumor localization, left behind at the end of cytoreductive
surgery, is more than 1 cm in diameter. •Debulking surgery feasible:
residual tumor after surgery will be < 1 cm. •Debulking surgery not
feasible: residual tumor after surgery will be > 1 cm.
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conventional staging are recorded in a case record form
(CRF). After randomization, but before surgery, patients
are asked to fill out a questionnaire consisting of items
regarding quality of life (EORTC QoL-C30 and QoL-
OV28, EQ-5D) and a questionnaire on additional home-
care (SF-HLQ). The same questionnaires are also asked
to be completed three months after start of treatment
and six weeks upon ending treatment. At local centres,
data collection is the responsibility of the local partici-
pating gynaecologist and research nurse. The data col-
lected in this study are coded and processed with
adequate precautions to ensure patients confidentiality.
Interventions
Debulking surgery should take place within 6 weeks
after randomization. When patients receive a laparo-
scopy this should be done within 3 weeks after randomi-
zation. After the laparoscopy the decision is made for
PDS or NACT with IDS after three courses of che-
motherapy. The diagnostic laparoscopy will, when possi-
ble, be performed by the referring gynaecologist in
attendance of the gynaecological oncologist. In case the
laparoscopy can not be attended by the gynaecological
oncologist and the laparoscopy can not be performed in
the centre hospital, the laparoscopic procedure will be
recorded completely. An open laparoscopy has to be
performed examining systematically the ovaries, fallo-
pian tubes, uterus, pelvic peritoneum, omentum, serosa
and mesentery of the large and small bowel, spleen,
liver surface, paracolic gutters and diaphragm. Tumour
localizations will be documented in size and position to
adjacent structures. To confirm diagnosis of ovarian
cancer biopsies of tumor localizations will be taken.
Judgment for incomplete cytoreduction will be made by
the gynaecological oncologist on the following
parameters:
- Extensive agglutinated intra-abdominal metastatic
disease
- Extensive serosal invasion of the intestines making
multiple bowel resections or more than 1,5 m of bowel
resection necessary in order to reach complete cytore-
ductive surgery.
- Extensive peritoneal carcinomatosis at the diaphrag-
matic level
After laparoscopy patients will be submitted to either
PDS within three weeks, followed by six courses of che-
motherapy consisting of Paclitaxel and Carboplatin or to
NACT followed by IDS and subsequent adjuvant che-
motherapy. Both primary and interval debulking sur-
geries will be performed in the center hospital or in the
referral hospital in collaboration with a gynaecological
oncologist according to standard procedures for
advanced ovarian cancer. The surgeon will describe the
localization and diameter of all tumor depositions before
surgery and of residual tumour in the surgical report
upon ending surgery. This will be done for 11 abdom-
inal regions. The amount of metastases will be classified
as 0, 1, 2-10, 11-50 and > 50 tumour deposits. The size
of the largest metastasis will be categorized into 0 mm,
≤ 10 mm, 11-20 mm, 21-50 mm, 51-100 mm and ≥ 100
mm in diameter. Furthermore the surgical procedures,
total length of the operation and blood loss will be
recorded.
Follow-up
As the primary outcome measure is the rate of subopti-
mal debulking surgery, this will be assessed at the end
of the surgical intervention. Data for secondary out-
comes will be assessed peri-operatively, during treat-
ment and at routine follow-up. All data will be
registered on a case record form (CRF) by the treating
physician and checked by the research nurse (status
review). For the economic evaluation use of health care
resources is assessed as part of the clinical data collec-
tion (CRF) and additional patient questionnaires. The
doctor registers resource utilization on a CRF related to
the use of operation time, duration of hospital ward and
ICU stay, additional diagnostic or therapeutic interven-
tions. The questionnaire addresses health related
resource use during follow-up, including visits to general
practitioners and other primary care providers, outpati-
ent visits and readmission, home care and informal care.
Adverse events will be followed until they have abated,
or until a stable situation has been reached. Data
regarding quality of life (QoL-C30, QoL-OV28, EQ-5D,)
are assessed with help of self reported questionnaires
before start of treatment, at 3 months and at the end of
treatment.
Outcome measures
Our primary outcome measure is the proportion of
debulking laparotomies with a largest residual tumour
of more than one centimetre in diameter (futile
laparotomy).
Our secondary outcome measures will be progression-
free and overall survival, the number of debulking sur-
gery leaving no residual tumour, debulking surgery in
which the largest residual tumour is less than 1 cm in
diameter, costs and quality of life.
Statistical analysis
Sample size
Considering the present rate of debulking surgeries for
ovarian cancer leaving more than one centimetre of resi-
dual tumour in the Netherlands after conventional sta-
ging is to be at most 40%, we estimate that after
laparoscopy this should be less than 20%. With a two-
sided significance level of 0.05 90 patients per arm have
Rutten et al. BMC Cancer 2012, 12:31
http://www.biomedcentral.com/1471-2407/12/31
Page 4 of 6
to be included to achieve a power of 80%. Considering
10% loss to follow-up and protocol violation, we plan to
enroll 200 patients.
Data analysis
The results of the randomized trial will be analyzed
according to the intention to treat principle. Difference
in the proportion of futile laparotomies in both arms
will be tested using a Chi-square test with a two-sided
significance level of 0.05. Prognostic value of standard
staging and staging with laparoscopy will be expressed
as sensitivity, specificity and predictive values. Standard
staging and standard staging with laparoscopy is consid-
ered true positive when subsequent suboptimal debulk-
ing surgery is correctly identified. Overall survival (OS)
and progression free survival (PFS) will be measured
from the date of randomization to respectively the date
of death and first documented date of progression. OS
and PFS will be calculated in both arms by the Kaplan-
Meier method. Treatment complications will be
reported in a contingency table. Quality of life will be
compared between both treatment arms at various time
points. We will make a subgroup analysis for number of
futile laparotomy for each gynaecologic-oncologic cen-
tre, FIGO stage and size of metastatic tumour seen at
laparoscopy or laparotomy.
Economic evaluation
The aim of the economic evaluation is to assess whether
the laparoscopy can reduce the number of futile primary
laparotomies and associated costs to an extent that at
least offsets the costs of this laparoscopy in all eligible
patients. A strategy that reduces the number of unne-
cessary laparotomies is considered preferable, even if
this does not improve survival, also if the costs gener-
ated by both strategies are comparable. The economic
analyses will be conducted from a societal perspective
including direct medical and direct non-medical costs.
Relevant costs components that will be taken into
account are costs of the laparoscopy and laparotomy,
operation time, hospital days, interventions for compli-
cations and intensive care admission. Indirect costs are
associated with home care, consisting of both profes-
sional care as well as informal care.
Discussion
Primary debulking surgery with the aim to leave no resi-
dual tumour is still considered as the standard treatment
for patients with advanced ovarian cancer. However,
more and more patients are submitted to IDS to reas-
sure better surgical results. A complete debulking, with-
out any residual tumour after surgery, should be
pursued to obtain the best prognosis. However, the
number of primary surgeries leaving residual tumor of
more than 1 cm in diameter, is up to 40%, while during
interval debulking surgery more often complete resec-
tion is achieved, without affecting survival [19,20]
Selecting patients who benefit from primary debulking
surgery, i.e. in whom complete surgery results are possi-
ble, should be optimized. In several institutes diagnostic
laparoscopy is already standard of care to determine
further treatment in ovarian cancer patients. Prospective
and retrospective studies showed that predictability of
surgical outcome with laparoscopy is better than that of
standard diagnostic staging [16-18,21]. However, predic-
tion models could not be validated in different popula-
tions. Furthermore, laparoscopy is an invasive procedure
under general anesthesia with a serious morbidity rate
of 1‰-5% [22,23]. If laparoscopy before starting treat-
ment is a reliable additional diagnostic tool in predicting
result of PDS, unsuccessful laparotomies can be pre-
vented. This will optimize treatment for the individual
patient. To this date no randomized controlled trials
have investigated whether additional diagnostic laparo-
scopy prevents unsuccessful laparotomies.
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